NBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
NovaBridge Biosciences
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 7, 2026
$1.30+0.04 (+3.17%)
Close on Oct 19, 2026
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
9.3%
25M of 265M shares
Institutional holders
49
13 new, 11 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
1 buys · 7 sales
Net bought $423.03K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| T Investment Limited | 8,172,022 | 9.89% | 13D (active) | Nov 22, 2023 |
| Everest Medicines Limited | 42,524,716 | 16.10% | 13D (active) | Aug 5, 2025 |
| Wei Fu | 30,499,709 | 11.50% | 13D (active) amendment | Jan 29, 2026 |
| Jingwu Zhang Zang | 10,454,937 | 5.60% | 13G (passive) amendment | Dec 31, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of NBP | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Hhlr Advisors, Ltd. | 5,980,568 | 2.25% | $11.66M | – | 1.40% |
| Morgan Stanley | 3,653,228 | 1.38% | $7.12M | −184,970 | 0.00% |
| AIHC Capital Management Ltd | 2,878,033 | 1.08% | $5.61M | +615,100 | 5.38% |
| Siren, L.L.C. | 2,004,739 | 0.76% | $3.91M | −995,261 | 0.08% |
| Marshall Wace, Llp | 1,231,946 | 0.46% | $2.40M | New | 0.00% |
| Candriam S.C.A. | 1,132,563 | 0.43% | $2.21M | – | 0.01% |
| Adage Capital Partners Gp, L.L.C. | 1,000,000 | 0.38% | $1.95M | – | 0.00% |
| Two Sigma Investments, LP | 851,348 | 0.32% | $1.66M | New | 0.00% |
| Renaissance Technologies LLC | 758,226 | 0.29% | $1.48M | +485,814 | 0.00% |
| BlackRock, Inc. | 686,208 | 0.26% | $1.34M | +58,712 | 0.00% |
| Citadel Advisors LLC | 622,831 | 0.23% | $1.21M | +456,215 | 0.00% |
| E Fund Management Co., Ltd. | 589,020 | 0.22% | $1.15M | New | 0.03% |
| Exome Asset Management LLC | 576,960 | 0.22% | $1.13M | – | 0.69% |
| State Street Corp | 360,376 | 0.14% | $702.73K | −9,731 | 0.00% |
| Woodline Partners LP | 350,000 | 0.13% | $682.50K | −350,000 | 0.00% |
| Fiera Capital Corp | 315,681 | 0.12% | $615.58K | – | 0.00% |
| UBS Group AG | 301,780 | 0.11% | $588.47K | +238,239 | 0.00% |
| Barclays PLC | 279,019 | 0.11% | $544.09K | −20,280 | 0.00% |
| Taikang Asset Management (Hong Kong) Co Ltd | 170,931 | 0.06% | $333.32K | – | 0.03% |
| Goldman Sachs Group Inc | 161,321 | 0.06% | $314.58K | +48,858 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 49 | 25M | 9.3% | 13 / 13 | 11 / 11 | 5M | 4M |
| Q1 2026 | 48 | 29M | 11.0% | 9 / 14 | 15 / 18 | 3M | 7M |
| Q4 2025 | 57 | 33M | 12.5% | 21 / 16 | 12 / 5 | 9M | 5M |
| Q3 2025 | 42 | 30M | 11.2% | 21 / 10 | 6 / 11 | 21M | 1M |
| Q2 2025 | 32 | 9M | 3.5% | 10 / 5 | 8 / 7 | 1M | 1M |
| Q1 2025 | 29 | 9M | 3.4% | 5 / 5 | 5 / 3 | 1M | 4M |
| Q4 2024 | 28 | 12M | 4.5% | 7 / 3 | 6 / 7 | 4M | 7M |
| Q3 2024 | 28 | 14M | 5.3% | 4 / 5 | 6 / 13 | 0M | 1M |
| Q2 2024 | 38 | 15M | 5.7% | 3 / 4 | 19 / 4 | 4M | 1M |
| Q1 2024 | 39 | 12M | 4.6% | 6 / 11 | 9 / 11 | 2M | 3M |
| Q4 2023 | 44 | 13M | 4.8% | 11 / 11 | 14 / 13 | 2M | 4M |
| Q3 2023 | 47 | 15M | 5.7% | 12 / 9 | 14 / 12 | 2M | 5M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of NBP | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Biotechnology ETF | 591,381 | 0.22% | $1.15M | 0.01% | Jun 30, 2026 |
| State Street(R) SPDR(R) Portfolio Emerging Markets ETF | 297,847 | 0.11% | $580.80K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 68,849 | 0.03% | $126.68K | 0.00% | May 31, 2026 |
| State Street(R) SPDR(R) S&P(R) Emerging Markets Small Cap ETF | 48,319 | 0.02% | $94.22K | 0.01% | Jun 30, 2026 |
| World ex U.S. Core Equity Portfolio | 26,330 | 0.01% | $42.13K | 0.00% | Jul 31, 2026 |
| Invesco NASDAQ Future Gen 200 ETF | 23,427 | 0.01% | $43.11K | 0.23% | May 31, 2026 |
| Emerging Markets Core Equity 2 Portfolio | 20,035 | 0.01% | $32.06K | 0.00% | Jul 31, 2026 |
| Emerging Markets Social Core Equity Portfolio | 15,130 | 0.01% | $24.21K | 0.00% | Jul 31, 2026 |
| State Street(R) SPDR(R) S&P(R) China ETF | 14,210 | 0.01% | $27.71K | 0.01% | Jun 30, 2026 |
| Emerging Markets Sustainability Core 1 Portfolio | 9,306 | 0.00% | $14.89K | 0.00% | Jul 31, 2026 |
| Invesco Nasdaq Biotechnology ETF | 5,925 | 0.00% | $10.90K | 0.02% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 5,100 | 0.00% | $9.95K | 0.00% | Jun 30, 2026 |
| ProShares Ultra Nasdaq Biotechnology | 4,151 | 0.00% | $7.64K | 0.01% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Srishti Gupta | Chief Executive Officer, Director | – | – | Jul 8, 2026 |
| Xi-Yong Fu | See Remarks, Director | 59,823 | 0.02% | Mar 18, 2026 |
| Phillip Andrew Dennis | Chief Medical Officer | 173,427 | 0.07% | Sep 21, 2026 |
| Sean Wuxiong Cao | Chief Bus. Development Officer | 266,467 | 0.10% | Sep 11, 2026 |
| Cong Claire Xu | EVP, Clinical Development | 304,201 | 0.11% | Sep 1, 2026 |
| Mark Arnold Hagler | Chief Commercial Officer | 230,000 | 0.09% | Jul 10, 2026 |
| Liwei Lorraine Lin | General Counsel | – | – | Jul 10, 2026 |
| Denny Hsueh Wen Chu | See Remarks | – | – | Mar 24, 2026 |
| Xiaofan Neo Zhang | Chief Investment Officer | 874,000 | 0.33% | Mar 18, 2026 |
| Adeline Yi Zhang | Global Controller | – | – | Mar 18, 2026 |
| Joanna Xuqiong Wu | See Remarks | 5,750 | 0.00% | Mar 18, 2026 |
| Ming Kyler Lei | Chief Financial Officer | – | – | Mar 18, 2026 |
| Martin William Dewhurst | Director | – | – | Sep 10, 2026 |
| Robert A. Lenz | Director | 17,218 | 0.01% | Aug 25, 2026 |
| Wei Fu | Director | 30,499,699 | 11.49% | Jun 30, 2026 |
| Conor Chia-hung Yang | Director | – | – | Apr 1, 2026 |
| Xin Liu | Director | – | – | Mar 18, 2026 |
| Chun Kwok Alan Au | Director | – | – | Mar 18, 2026 |
| Ian Ying Woo | Director | – | – | Mar 18, 2026 |
| Emmett Cunningham | Director | – | – | Mar 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Phillip Andrew Dennis Chief Medical Officer | Sep 18, 2026 | Sale | −8,209 | $0.71 | $5.83K | 173,427 |
| Phillip Andrew Dennis Chief Medical Officer | Sep 17, 2026 | Option exercise | +23,695 | – | – | 181,636 |
| Sean Wuxiong Cao Chief Bus. Development Officer | Sep 9, 2026 | Sale | −107,978 | $0.74 | $79.90K | 266,467 |
| Sean Wuxiong Cao Chief Bus. Development Officer | Sep 3, 2026 | Option exercise | +235,136 | – | – | 270,209 |
| Sean Wuxiong Cao Chief Bus. Development Officer | Sep 3, 2026 | Option exercise | +104,236 | – | – | 374,445 |
| Cong Claire Xu EVP, Clinical Development | Aug 31, 2026 | Sale | −3,282 | $0.79 | $2.59K | 304,201 |
| Cong Claire Xu EVP, Clinical Development | Aug 30, 2026 | Option exercise | +9,382 | – | – | 307,483 |
| Robert A. Lenz Director | Aug 22, 2026 | Option exercise | +17,218 | – | – | 17,218 |
| Cong Claire Xu SVP, Clinical Development | Jul 6, 2026 | Sale | −4,485 | $0.89 | $3.99K | 298,101 |
| Cong Claire Xu SVP, Clinical Development | Jul 4, 2026 | Option exercise | +12,432 | – | – | 302,586 |
| Phillip Andrew Dennis Chief Medical Officer | Jun 18, 2026 | Sale | −8,494 | $0.66 | $5.61K | 157,941 |
| Phillip Andrew Dennis Chief Medical Officer | Jun 17, 2026 | Option exercise | +23,695 | – | – | 166,435 |
| Cong Claire Xu SVP, Clinical Development | Jun 1, 2026 | Sale | −3,494 | $3.94 | $13.77K | 290,154 |
| Cong Claire Xu SVP, Clinical Development | May 30, 2026 | Option exercise | +9,382 | – | – | 293,648 |
| Sean Wuxiong Cao See Remarks, Director | May 14, 2026 | Sale | −21,399 | $1.99 | $42.58K | 35,073 |
| Mark Arnold Hagler See Remarks | Apr 24, 2026 | Buy | +230,000 | $2.51 | $577.30K | 230,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Phillip Andrew Dennis Chief Medical Officer | Sep 18, 2026 | 3,569 | $5.80K | Sep 18, 2026 | Restricted Stock Vesting |
| Sean Wuxiong Cao Officer, CHIEF BUSINESS DEVELOPMENT OFFICER | Sep 9, 2026 | 46,947 | $79.38K | Sep 9, 2026 | RESTRICTED STOCK UNITS VESTING |
| Sean Wuxiong Cao Officer, CHIEF BUSINESS DEVELOPMENT OFFICER | May 14, 2026 | 9,304 | $18.53K | May 14, 2026 | RESTRICTED SHARE UNITS VESTING |
| Phillip Andrew Dennis Chief Medical Officer | Mar 18, 2026 | 3,638 | $10.15K | Mar 18, 2026 | Restricted Stock units Vesting |
| Joseph W. Skelton Officer, FORMER CFO | Jan 2, 2026 | 120,000 | $519.60K | Jan 2, 2026 | STOCK OPTION EXERCISE AND SALE PURSUANT TO 10B51 PLAN |
| Phillip Andrew Dennis CHIEF MEDICAL OFFICER | Dec 18, 2025 | 3,431 | $14.50K | Dec 18, 2025 | Restricted Stock Units Vesting |
| Raj Kannan Officer, CEO | Jul 26, 2024 | 50,000 | $69.50K | Jul 26, 2024 | ACQUIRED STOCK UNDER COMPANY SHARE INCENTIVE PLAN |
| Raj Kannan Officer, CEO | Jul 17, 2024 | 300,000 | $489.00K | Jul 17, 2024 | ACQUIRED STOCK UNDER COMPANY SHARE INCENTIVE PLAN |
| Gigi Qi Feng Officer, CHIEF COMMUNICATIONS OFFICER | Mar 15, 2024 | 150 | $270 | Mar 15, 2024 | ACQUIRED STOCK UNDER THE COMPANY SHARE INCENTIVE PLAN |
| Weimin Tang Officer, CHIEF BUSINESS OFFICER | Feb 8, 2024 | 20,000 | $40.00K | Feb 8, 2024 | ACQUIRED STOCK UNDER COMPANY SHARE INCENTIVE PLAN |
| Andrew Zhu Officer, PRESIDENT AND ACTING CEO | Jan 5, 2024 | 30,000 | $63.60K | Jan 5, 2024 | ACQUIRED STOCK UNDER COMPANY SHARE INCENTIVE PLAN |
| Richard Cheng Li Officer, CHIEF LEGAL OFFICER | Dec 29, 2023 | 85,700 | $156.83K | Dec 29, 2023 | ACQUIRED STOCK NDER COMPANY SHARE INCENTIVE PLAN |
| Gigi Qi Feng Officer, CHIEF COMMUNICATION OFFICER | Dec 26, 2023 | 20,000 | $31.00K | Dec 26, 2023 | ACQUIRED STOCK NDER COMPANY SHARE INCENTIVE PLAN |
| Richard Cheng Li Officer, CHIEF LEGAL OFFICER | Nov 16, 2023 | 85,700 | $147.40K | Nov 16, 2023 | ACQUIRED STOCK UNDER COMPANY SHARE INCENTIVE PLAN |
| Medicines Ltd Everest 10% Stockholder | Oct 10, 2023 | 6,078,555 | $4.47M | Oct 24, 2023 | Private placement |